CHMP recommends OK for Alnylam's patisiran; Amgen scraps a BCMA ADC
→ Alnylam $ALNY took another big step toward getting a European approval for patisiran. The biotech says that the CHMP recommended an OK for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. A formal OK is likely. The drug is facing an August 11 PDUFA date at the FDA.
→ Portola $PTLA, though, isn’t making any headway with betrixaban. The CHMP batted back the company’s appeal of its earlier rejection. Here’s a summary of all the action at the EMA today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
